BR 3409
Alternative Names: BR-3409; BR3409-1; BR3409-2Latest Information Update: 30 May 2025
At a glance
- Originator Boryung Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 26 Mar 2025 Boryung Pharmaceutical completes a phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT06879158)
- 07 Dec 2024 Boryung Pharmaceutical completes a phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT06879132)
- 10 Nov 2024 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT06879158)